RecruitingNot ApplicableNCT06896994

Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia

Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia

Sponsor

Beijing Tiantan Hospital

Enrollment

150 participants

Start Date

Apr 1, 2025

Study Type

INTERVENTIONAL

Conditions

Postherpetic Neuralgia

Summary

To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Ages more than 18 years;
Pain present for more than 3 months after healing of a herpes zoster skin rash;
Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；
Failed to respond to or tolerate the effective dose of pregabalin monotherapy.

Exclusion Criteria13

Obstructive sleep apnoea syndrome;
Those who receive interventional treatments;
A history of systemic immune diseases, organ transplantation, or cancers;
A history of severe cardiopulmonary, hepatic or renal dysfunction;
A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
Currently using monoamine oxidase inhibitors (MAOIs);
Having untreated angle-closure glaucoma;
Those suffering from increased intracranial pressure；
Comorbid hyperthyroidism or phaeochromocytoma;
Suspected or confirmed history of drug abuse;
Having contraindications to esketamine, pregabaline or duloxetine;
Communication difficulties;
Women who are preparing for pregnancy, in the pregnancy or lactation period.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGesketamine group

In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.

DRUGcontrol group

receiving the combination of pregabalin and duloxetine